Schedule 13G ownership disclosure

BioMarin Pharmaceutical Inc

Common Stock, par value $0.001 per share · CUSIP: 09061G101

Event date: 2025-06-30

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • VIKING GLOBAL INVESTORS LP

    Shares: 12,288,611 · Class: 6.4%

  • VIKING GLOBAL PERFORMANCE LLC

    Shares: 8,208,825 · Class: 4.3%

  • Viking Global Equities II LP

    Shares: 164,175 · Class: 0.1%

  • Viking Global Equities Master Ltd.

    Shares: 8,044,650 · Class: 4.2%

  • Viking Long Fund GP LLC

    Shares: 2,856,671 · Class: 1.5%

  • Viking Long Fund Master Ltd.

    Shares: 2,856,671 · Class: 1.5%

  • Viking Global Opportunities Parent GP LLC

    Shares: 1,223,115 · Class: 0.6%

  • Viking Global Opportunities GP LLC

    Shares: 1,223,115 · Class: 0.6%

  • Viking Global Opportunities Portfolio GP LLC

    Shares: 1,223,115 · Class: 0.6%

  • Viking Global Opportunities Liquid Portfolio Sub-Master LP

    Shares: 1,223,115 · Class: 0.6%

  • HALVORSEN OLE ANDREAS

    Shares: 12,288,611 · Class: 6.4%

  • Ott David C.

    Shares: 12,288,611 · Class: 6.4%

  • Shabet Rose Sharon

    Shares: 12,288,611 · Class: 6.4%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000905148-25-002994
Form type
SCHEDULE 13G/A
Filer
BIOMARIN PHARMACEUTICAL INC
CIK
CIK 1048477
Filed
Aug 14, 2025
Reporting period
Jun 30, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub